Cushing Syndrome Clinical Trial
Official title:
Prévalence de la stéato-fibrose hépatique Dans le Syndrome de Cushing
Cushing's Syndrome is a rare disease resulting from prolonged exposure to high levels of circulating cortisol. Clinical manifestations are variable but many patients present a metabolic syndrome (abdominal obesity, insulin resistance, dyslipidemia, hypertension). With regard to the liver, experimental data have shown that excess cortisol leads in an increase in lipogenesis and a reduction in the oxidation of fatty acids. This, in association with an accumulation of visceral adipose tissue and deregulation of adipokines, may contribute to the development of hepatic steatosis in animals. However, few data is available in humans with only one study of 50 patients with Cushing's syndrome estimating the prevalence of hepatic steatosis at 20%. NAFLD (Non-Alcoholic Fatty Liver Disease), is defined as the presence of hepatic steatosis in the absence of secondary causes of intrahepatic fat accumulation. It is a heterogeneous disease ranging from simple liver steatosis, whose prognosis is generally considered to be benign, to inflammation (NASH, Non-Alcoholic Steato-Hepatitis) which may progress to fibrosis, cirrhosis and an increased risk of hepatocellular carcinoma. The prognosis for NAFLD is mainly related to the severity of hepatic fibrosis. In Cushing's syndrome, normalization of cortisol production is the most effective strategy to improve co-morbidities associated with hypercortisolism. However, some of these complications, especially the metabolic co morbidities, could not be completely reversible and no data is available about resolution of hepatic steatosis.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06050057 -
Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
|
||
| Recruiting |
NCT00669266 -
Adrenal Tumors - Pathogenesis and Therapy
|
||
| Terminated |
NCT03379363 -
Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
|
||
| Recruiting |
NCT06008184 -
Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
|
||
| Recruiting |
NCT05911620 -
Evaluation of the Severity of Hepatic Fibrosis by Magnetic Resonance Elastography in the Diagnosis of Endogenous Hypercorticism
|
N/A | |
| Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
| Recruiting |
NCT04045015 -
Liquorice and Salivary Cortisol
|
N/A | |
| Recruiting |
NCT05804669 -
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT03474237 -
A Prospective Cohort Study for Patients With Adrenal Diseases
|
||
| Recruiting |
NCT03343470 -
The Circadian Rhythm in CusHing SyndrOme in Active Phase and dUring RemiSsion (TheHOURS)
|
||
| Recruiting |
NCT03364803 -
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
|
||
| Terminated |
NCT02001051 -
Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism
|
Phase 2 | |
| Active, not recruiting |
NCT03697109 -
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
|
Phase 3 | |
| Enrolling by invitation |
NCT03604198 -
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
|
Phase 2 | |
| Completed |
NCT05347979 -
Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
|
Phase 1 | |
| Recruiting |
NCT01382420 -
Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma
|
N/A | |
| Completed |
NCT00001849 -
New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
|
Phase 2 | |
| Recruiting |
NCT06229405 -
Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data
|
||
| Recruiting |
NCT03211624 -
Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome
|
||
| Not yet recruiting |
NCT06326853 -
Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models
|